A Leader in the Discovery and Development of First- and Best-in-class Small Molecule Cancer Therapies

Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Our expertise is in designing inhibitors of protein-protein interactions (PPIs) to restore apoptosis, or programmed cell death. We have eight clinical candidates in Phase 1 or 2 studies in the U.S., Australia and China. Our clinical candidates include a novel Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage is bringing innovative therapies to patients across the world for cancers and other diseases, using expertise in compounds that affect programmed cell death.